Haemonetics (HAE): Reassessing Valuation After a 55% Three-Month Share Price Surge

Haemonetics (HAE) has quietly rallied, with shares up roughly 23% over the past month and more than 55% in the past 3 months, prompting investors to recheck the story behind this med-tech name.

See our latest analysis for Haemonetics.

At a share price of $83.94, that 90 day share price return of 54.76% stands in sharp contrast to a modest 1 year total shareholder return of just 1.21%. This suggests fresh momentum as investors warm to its growth and profitability story.

If Haemonetics has you rethinking opportunities in healthcare, this could be a good moment to explore other potential winners across healthcare stocks for fresh ideas.

With earnings growing faster than revenue and the shares now hovering just below analyst targets, investors face a key question: Is Haemonetics still trading below its true worth, or is future growth already fully priced in?

Most Popular Narrative Narrative: 1% Undervalued

With Haemonetics closing at $83.94 against a narrative fair value of about $84.55, the story leans toward modest upside grounded in execution.

Enterprise-wide portfolio transformation highlighted by the divestiture of low-margin businesses, disciplined capital deployment, and ongoing investment in automation and digital solutions is driving substantial gross and operating margin expansion (guidance of 26-27% for FY26) and is likely to support further improvements in net margins and free cash flow conversion.

Read the complete narrative.

Want to see how margin gains, disciplined capital moves, and a future earnings multiple all justify this valuation? The narrative unpacks a detailed, numbers driven roadmap.

Result: Fair Value of $84.55 (ABOUT RIGHT)

Have a read of the narrative in full and understand what's behind the forecasts.

However, sustained underperformance in VASCADE, or intensifying U.S. competition across its core platforms, could quickly challenge today’s upbeat margin and growth expectations.

Find out about the key risks to this Haemonetics narrative.

Build Your Own Haemonetics Narrative

If you see the story differently or want to stress test the numbers yourself, you can build a custom view in just minutes: Do it your way.

A great starting point for your Haemonetics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Ready for your next investing move?

Use the Simply Wall Street Screener now to uncover fresh, data backed ideas before the crowd notices, and keep your portfolio positioned where the momentum is building.

• Capture fast growing innovation by targeting these 26 AI penny stocks that could reshape entire industries with scalable, real world applications.
• Lock in dependable income potential with these 15 dividend stocks with yields > 3% that aim to combine yield strength with sustainable payout profiles.
• Capitalize on mispriced opportunities through these 904 undervalued stocks based on cash flows that the market may be overlooking based on future cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com